The Cannavist Issue 6 B2C | Page 55

August 2019 The Home Office defines criteria for granting licences for plant cultivation, saying: “There needs to be a defined commercial end use and the Home Office only issues licences for cultivation of plants f rom approved seed types with a THC content not exceeding 0.2%.” On CBD: “For a CBD and other cannabinoid product to be lawfully available for human consumption it needs to either meet the Exempted Product Criteria in Regulation 2 of the MDR 2001 or the definition of a CBPM in Schedule 2 to the MDR 2001 for its possession to be lawful.” March 5, 2020 The German Federal Government backtracks on the developments of December, siding with the European Industrial Hemp Association (EIHA) stating that food containing parts of the hemp plant are not novel. “Foodstuffs containing parts of the hemp plant are in principle not ‘novel’ foods within the meaning of regulation (EU 2015/2283).” January 1, 2021 November 2019 Rumours start circulating about CBD regulations at GCI Europe, a two-day cannabis conference in London. CBD companies start to ask questions of health care, food and CBD speakers about what the regulations or process is likely to be. December 2019 Following a court case, German authorities confirm they view CBD as prescription medicine or a novel food. February 2020 The UK’s FSA announces a deadline for CBD companies to comply with testing, labelling and the Novel Foods Act. After this date, the local authorities will enforce the legislation. Vulnerable people should avoid CBD and those who take it should not take more than 70mg daily. The recommended submission start date to allow for any questions to be directed at the FSA. “We can then give businesses guidance and answer any queries they may have, in order to ensure they progress at pace through our UK authorisation process f rom January 1 2021.” March 31, 2021 The final deadline to submit food products for testing. Products cannot be on the shelves unless they are clearly labelled, transparent about ingredients and carry authorisation f rom the FSA. “A novel food must not differ in a way that the consumption of the novel food would be nutritionally disadvantageous for the consumer.” 55